Drug Profile
Research programme: oligonucleotide therapeutics for pain - OliPass
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator OliPass
- Class Analgesics; Oligonucleotides
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 05 Sep 2023 Preclinical development in Neuropathic-pain is still ongoing in South Korea (Olipass pipeline, September 2023)
- 12 Jul 2016 Preclinical trials in Neuropathic pain in South Korea (unspecified route)